SCHEMBL9890655

SCHEMBL9890655

O=C(O)Cc1cc(F)ccc1-c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.49
CHRM1 P11229 4/20 0.46
PTGDR2 Q9Y5Y4 3/20 0.44
SUCNR1 Q9BXA5 1/20 0.44
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER3 P43115 1/20 0.43
PTGER2 P43116 1/20 0.43
FFAR1 O14842 2/20 0.43
FFAR4 Q5NUL3 2/20 0.43
SHMT1 P34896 2/20 0.42
CNR1 P21554 1/20 0.42
CHRM3 P20309 2/20 0.42
AKR1A1 P14550 1/20 0.42
AKR1B1 P15121 1/20 0.42
DCLRE1B Q9H816 1/20 0.42
HMGCR P04035 1/20 0.41
SHMT2 P34897 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890653 0.89 PPARG (0.49) PPARGCHRM1PTGDR2SUCNR1AKR1C3
SCHEMBL9890674 0.89 SUCNR1 (0.46) PPARGCHRM1PTGDR2SUCNR1AKR1C3
SCHEMBL9890671 0.88 PTGDR2 (0.50) PPARGPTGDR2PTGER1PTGER4PTGER3
SCHEMBL3738385 0.88 SUCNR1 (0.50) CHRM1PTGDR2SUCNR1PTGER1PTGER4
SCHEMBL2395113 0.87 CHRM1 (0.45) PPARGCHRM1SHMT1CNR1CHRM3
SCHEMBL3731501 0.85 FFAR1 (0.54) PPARGPTGDR2PTGER1PTGER4PTGER3
SCHEMBL3736882 0.84 AKR1C3 (0.49) PPARGPTGDR2SUCNR1AKR1C3AKR1C2
SCHEMBL9890642 0.82 CHRM1 (0.57) CHRM1SUCNR1PTGER1PTGER4PTGER3
SCHEMBL3735666 0.81 FABP4 (0.45) CHRM1PTGDR2SUCNR1AKR1C3AKR1C2
SCHEMBL3749563 0.80 TSHR (0.47) PPARGPTGDR2FFAR1FFAR4AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PPARG 2516/4885CHRM1 340/4885PTGDR2 1062/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PPARG 2516/4885CHRM1 340/4885PTGDR2 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.